TILIZERS (SHRI EDUARDO FALEIRO) : (a) to (d) Information to the extent available is given in the Statement (*see* below).

(e) The prices of drugs outside price control are not maintained.

Statement

	Name of the company/ product	A/c	Production		
		Unit	1990-91	1991-92	1992-93
1.	CHLOROPROPAMIDE	T			
	(a) Albert David		38.45	-	16.75
	(b) Kothari Plantation		28.00	39.60	33.63
	(c) Pfizer		29.12	44.38	44.42
2.	TINIDAZOLE	T			
	(a) Cadila Labs.		6.58	9.50	3.83
	(b) Euphoric Drugs		24.64	27.76	29.88*
	(c) FDC Ltd.		0.02	-	-
	(d) Lyka Labs.		7.35	-	-
	(e) Metroni Drugs		7.95	13.19	21.95
	(f) Morani Chemicals		-	-	-
3.	GLYBENCLAMIDE SUBS.	T			
	(a) Bochringer-Knoll		0.58	1.23	0.71
	(b) Hoechst		2.49	2.80	2.96
	(c) Cadila		-	-	0.76
4.	BARALGAN KETONE	T			
	(a) Hoechst India		2.49	2.50	3.27
5.	FRUSEMIDE	T			
	(a) Hoechst India		7.80	7.59	8.57
6.	TRIMETHOPRIM	T			
	(a) Anglo French		0.03	-	-
	(b) Burroughs Wellcome		70.89	97.02	83.99
	(c) German Remedies		6.17	7.38	6.33
	(d) IPCA		26.41	18.44	25.30
	(e) Standard Organics		99.39	121.57	226.63*
	(f) Inventa Chem.		141.25	133.08	89.50
7.	ISOXCUPRIN HCL.	T			
	(a) Duphar Interfran		1.91	1.55	1.88
8.	PARACHLORO META XYLENOL	T			
	(a) Reckitt & Colman		88.46	110.10	120.08*
9.	RANITIDINE	T			
	(a) Glaxo		25.56	19.55	33.10
	(b) Globle Organics		87.78	110.44	123.75
	(c) Ranbaxy Labs.		13.81	8.24	14.84
	(d) Unichem Labs.		-	0.43	0.36

*Estimated.

Import of Intermediates/Penultimates by Drug Companies

4176. PROF. I. G. SANADI : Will the PRIME MINISTER be pleased to state :

(a) whether it is a fact that under the Drug Policy, 1986 all existing units which are producing drugs from intermediates/penultimates are producing drugs from intermediates/penultimates are required to furnish details of imports made from their principals or their associates within one month of the import;

(b) if so, the names of the companies which provided such information and what are the details of each;

(c) what are the details of proposals cleared under Phased Manufacturing Programme under Drug Policy, 1986 and what is the position of each;

(d) what was the import content to ex-factory value in each case;

(e) whether Government are monitoring the imports of intermediates and penultimates; and

(f) if so, what was the total import of Drug intermediates/penultimates and other raw materials during the last three years, year-wise?

THE MINISTER OF STATE IN THE MINISTRY OF CHEMICALS AND FERTILIZERS (SHRI EDUARDO FALEIRO) : (a), (b), (e) and (f) According to Para 6.7 of the Drug Policy 1986, "all companies manufacturing bulk drugs are required to submit to the Govt. their Phased Manufacturing Programme (PMP) proposals and the existing companies which import drug intermediates or their raw materials from their principals or their associated companies are required to inform the Government of the details of such transactions within a month of such import". However, the compliance by the Industry in this respect has been only partial. The background note on the Review of Drug Policy has been discussed in the House during the current session.

(c) and (d) The number of bulk drug manufacturing approvals, by fixing basic stages as required under PMP of the Drug Policy, is large.

Urea Production by Sindri Unit of FCI

4177. SHRI GAYA SINGH: Will the PRIME MINISTER be pleased to state :

(a) whether it is a fact that the Sindri Unit of the Fertilizer Corporation of India Ltd. is producing urea at its rated capacity and crossed the target fixed for the year 1992-93;

(b) if so, the same level of production there of for not achieving during the first half of the said year; and

(c) what are the plans of government for Sindri unit for continuing production?

THE MINISTER OF STATE IN THE MINISTRY OF CHEMICALS AND FERTILIZERS (SHRI EDUARDO FALEIRO) : (a) and (b) The Sindri unit produced 2.95 Lakh tonnes of urea during the year 1992-93 against its annual rated/licensed capacity of 3.30 lakh tonnes. However, the unit produced more than the target of 2.48 lakh tonnes fixed for the year 1992-93. The production during first half of the year was lower than the second half due to equipment breakdown and liquidity problems.

(c) FCI is implementing a revamping scheme for Sindri unit at an estimated cost of Rs. 16.23 crores, including a provision of Rs. 10.078 crores for revamping of its Captive Power Plant. FCI has already spent Rs. 4.46 crores on the scheme. FCI has also other schemes estimated to cost Rs. 33.30 crores for modernising their Sindri plant. In the meantime, FCI has been declared a sick company by the Board for Industrial and Financial Reconstruction (BIFR) under the Sick Industrial Companies (Special Provisions) Act, 1985.

मध्य प्रदेश में पर्यटक स्थलों के विकास पर खर्च की गई राशि

4178. **श्री दिलीप सिंह जूदेव** : क्या नागर विमानन और पर्यटन मंत्री यह बताने की कृपा करेंगे कि :

(क) मध्य प्रदेश में वर्ष 1991-92 और 1992-93 के दौरान प्राकृतिक सौन्दर्य स्थलों और ऐतिहासिक महत्व के स्थानों को पर्यटन की दृष्टि से अधिक उपयोगी और आकर्षक बनाने के लिए कितनी-कितनी राशि खर्च की गयी और ऐसे स्थानों के नाम क्या हैं ;

(ख) उक्त वर्षों के दौरान राज्य में पर्यटन की दृष्टि से नये स्थानों के विकास पर कितनी धनराशि खर्च की गई थी, और ऐसे स्थानों के नाम क्या है; और

(ग) प्रदेश के आदिवासी बहुल क्षेत्रों में प्राकृतिक सौन्दर्य के स्थलों के पर्यटन की दृष्टि से विकास के लिए किन स्थलो पर कितनी राशि व्यय की गई तथा इन स्थलों पर पर्यटकों के जाने एवं आकर्षित होने का ब्यौरा क्या है ?

नागर विमानन और पर्यटन मंत्री (श्री गुलाम नबी आज़ाद) : (क) और (ख) 1991-92 और 1992-93 के दौरान मध्यप्रदेश राज्य में पर्यटक स्थलों का विकास करने के लिए स्वीकृत परियोजनाएं/स्कीमें और तत्समुक्त राशि विवरण I तथा II में की गई हैं (नीचे देखिये) ।

(ग) मध्य प्रदेश राज्य सरकार से प्राप्त पूरे प्रस्तावों के आधार पर उपयुक्त अवधि के दौरान आदिवासी क्षेत्रों में